Compare Amgen, Inc. (AMGN) vs CleanSpark Inc (CLSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs CleanSpark Inc — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while CleanSpark Inc trades at $12.34 (market cap $3.30B). The key difference: Amgen, Inc. is far larger — about 59.4× CleanSpark Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while CleanSpark Inc pays none. Which is the better fit depends on your goals.
| AMGN | CLSK | |
|---|---|---|
Market Cap | $196.12B | $3.30B |
Sector | Health | Technology |
52-Week High | $388.16 | $23.20 |
52-Week Low | $271.18 | $8.18 |
Enterprise Value | $241.41B | $4.15B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CleanSpark (CLSK) trades at $12.85, down 0.31% on the day, with a bearish technical signal. The company reported strong 2025 revenue of $766 million and net income of $364 million, but forecasts a significant net loss of -$501 million for 2026. Recent operational updates highlight bitcoin mining activities and management team expansion, while analyst consensus remains unanimously bullish with a $21.43 price target.
The stock presents a high-risk, high-reward profile. Analyst optimism contrasts with negative earnings surprises and projected profitability challenges. Key risks include execution on growth initiatives, volatile cash flows, and intense competition in the data center sector. The current price offers substantial upside to targets if the company can achieve its operational goals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →
